HIV Drug to Aid Melanoma Therapies?

Publication date: 14 March 2016
Source:Cancer Cell, Volume 29, Issue 3
Author(s): Hyungsoo Kim, Ze'ev A. Ronai
The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.

Teaser

The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith et al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.


from Cancer via ola Kala on Inoreader http://ift.tt/22gGWNg
via IFTTT